The Formerly #1 Most Prescribed Wound Cream in Dermatology is Back!2

The Formerly #1 Most Prescribed Wound Cream in Dermatology is Back!2

Rx-Strength Luxamend Decreases Average Healing Time for Wounds3,4

MOHS Surgical Wounds

50% faster time to wound closure than antibacterial ointment (6 weeks vs. 12 weeks) in a 12-week, parallel-group study, where 24 patients were scheduled for Mohs surgery and were randomized to a trolamine-containing topical emulsion or an antibacterial ointment.3

12-week, parallel-group study, 24 patients who were scheduled for Mohs micrographic surgery were randomized either to a trolamine-containing topical emulsion or to the antibacterial combination of bacitracin zinc/polymyxin B sulfate ointment. Treatments were applied for 6 weeks or until wound re-epithelialization, whichever came first. Efficacy and safety assessments included investigator reporting of wound size and application-site appearance at weeks 3, 6, and 12.3

Cryotherapy Lesions

21.4% faster time to healing than non-medicated petrolatum ointment (9.27 days vs. 11.8 days) in a 4-week, split-body study, where 40 patients were randomized and instructed to apply the trolamine-containing topical emulsion twice daily to lesions on one side of the body and a nonmedicated petroleum-based ointment to lesions on the other side of the body.3,4

Investigator-blinded, randomized, split-body (target region), 4-week trial enrolled 40 adults with Actinic Keratoses (AK) on the dorsal hands, dorsal forearms, forehead, and/or cheeks. AK lesions were treated with liquid nitrogen cryotherapy, and patients were instructed to apply a trolamine-containing topical emulsion twice daily to all treated regions on one side of the body and a nonmedicated petrolatum-based ointment to the treated regions on the other side of the body. Patients maintained diaries to record healing, and investigators assessed healing at week 4.3,4

Shave Biopsies

51% reduction in wound size by Week 1 and complete healing by Week 4 in a 4-week, open-label, single-group study, where 12 patients applied a trolamine-containing emulsion twice daily to their shave biopsy wound. The baseline mean wound size was 70.9 mm2.5

Single-center, open-label, single-group study evaluating the efficacy and safety of a trolamine-containing topical emulsion for enhancing wound healing after shave biopsy. Fifteen participants applied trolamine-containing topical emulsion twice daily to the entire wound area for 4 weeks. Wound healing was evaluated at weeks 1, 2, and 4.5

Luxamend® may be used for the dressing and management of wounds, including:

  • Mohs Surgical Wounds
  • Cryotherapy Lesions
  • Shave Biopsies
  • Full Thickness Wounds
  • Pressure Sores
  • Dermal Ulcers including Lower Leg Ulcers
  • Superficial Wounds
  • Minor Abrasions
  • Dermal Donor and Graft Site Management
  • Sunburns
  • 1st and 2nd degree burns
  • Radiation Dermatitis

Rx-Strength Luxamend Decreases Average Healing Time for Wounds3,4

MOHS Surgical Wounds

50% faster time to wound closure than antibacterial ointment (6 weeks vs. 12 weeks) in a 12-week, parallel-group study, where 24 patients were scheduled for Mohs surgery and were randomized to a trolamine-containing topical emulsion or an antibacterial ointment.3

12-week, parallel-group study, 24 patients who were scheduled for Mohs micrographic surgery were randomized either to a trolamine-containing topical emulsion or to the antibacterial combination of bacitracin zinc/polymyxin B sulfate ointment. Treatments were applied for 6 weeks or until wound re-epithelialization, whichever came first. Efficacy and safety assessments included investigator reporting of wound size and application-site appearance at weeks 3, 6, and 12.3

Cryotherapy Lesions

21.4% faster time to healing than non-medicated petrolatum ointment (9.27 days vs. 11.8 days) in a 4-week, split-body study, where 40 patients were randomized and instructed to apply the trolamine-containing topical emulsion twice daily to lesions on one side of the body and a nonmedicated petroleum-based ointment to lesions on the other side of the body.3,4

Investigator-blinded, randomized, split-body (target region), 4-week trial enrolled 40 adults with Actinic Keratoses (AK) on the dorsal hands, dorsal forearms, forehead, and/or cheeks. AK lesions were treated with liquid nitrogen cryotherapy, and patients were instructed to apply a trolamine-containing topical emulsion twice daily to all treated regions on one side of the body and a nonmedicated petrolatum-based ointment to the treated regions on the other side of the body. Patients maintained diaries to record healing, and investigators assessed healing at week 4.3,4

Shave Biopsies

51% reduction in wound size by Week 1 and complete healing by Week 4 in a 4-week, open-label, single-group study, where 12 patients applied a trolamine-containing emulsion twice daily to their shave biopsy wound. The baseline mean wound size was 70.9 mm2.5

Single-center, open-label, single-group study evaluating the efficacy and safety of a trolamine-containing topical emulsion for enhancing wound healing after shave biopsy. Fifteen participants applied trolamine-containing topical emulsion twice daily to the entire wound area for 4 weeks. Wound healing was evaluated at weeks 1, 2, and 4.5

Luxamend® may be used for the dressing and management of wounds, including:

  • Mohs Surgical Wounds
  • Cryotherapy Lesions
  • Shave Biopsies
  • Full Thickness Wounds
  • Pressure Sores
  • Dermal Ulcers including Lower Leg Ulcers
  • Superficial Wounds
  • Minor Abrasions
  • Dermal Donor and Graft Site Management
  • Sunburns
  • 1st and 2nd degree burns
  • Radiation Dermatitis

Antibiotic-Free1|Allergen-Free Fragrance1|Cosmetically Elegant Formulation

Antibiotic-Free
Allergen-Free Fragrance
Cosmetically Elegant Formulation

Important Safety Information

Indications and Usage

Luxamend® is indicated for use in:

  • Full Thickness Wounds, Pressure Sores, Dermal Ulcers including Lower Leg Ulcers
  • Superficial Wounds
  • 1st and 2nd Degree Burns, including Sunburns
  • Dermal Donor and Graft Site Management
  • Radiation Dermatitis
  • Minor Abrasions

Contraindications

Luxamend is contraindicated for use on bleeding wounds, skin rashes related to food or medicine allergies, and when an allergy to one of the ingredients is known.

Warnings

  • In radiation therapy, Luxamend may be applied as directed by the treating physician. Do not apply 4 hours prior to a radiation session.
  • Do not apply Luxamend to dermal grafts until after the graft has successfully taken.
  • Keep out of the reach of children.

Precautions

  • For the treatment of any dermal wound, consult a physician. Use Luxamend only as directed.
  • Luxamend does not contain a sunscreen and should not be used prior to extended exposure to the sun.
  • The use of Luxamend on skin rashes due to allergies has not been studied sufficiently and therefore is not recommended.
  • If clinical signs of infection are present, appropriate treatment should be initiated. If clinically indicated, use of Luxamend may be continued during the anti-infective therapy.
  • If condition does not improve within 10-14 days, consult a physician.

Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of medical products to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Full Prescribing Information.

REFERENCES:
1. LUXAMEND® Prescribing Information. Journey Medical Corporation, Scottsdale, AZ, 2023.
2. Symphony Health Solutions PHAST IDV Monthly TRx Data 2016 – 2018 (TRx market data includes: Biafine®, Sonafine®, Bionect®, Prutect™, Avo Cream™).
3. Cohen JL, Lorizzo JL and Kircik LH. Use of a topical emulsion for wound healing. 2007. J Support Oncol. 10 Suppl 5:1-9.
4. Del Rosso, JQ. Healing Wounds After Cryotherapy. 2007. The Dermatologist. Accessed at http://www.the-dermatologist.com/article/7144. Access date: 10/9/2015.
5. Kircik, LH. Study of Trolamine-Containing Topical Emulsion for Wound Healing after Shave Biopsy. 2009. Cutis. 83:326-332.

Luxamend is a registered trademark of Journey Medical Corporation.
All rights reserved. ©2023 Journey Medical Corporation. August 2023 LUX-M02-R00